Clinical Trials
32 trialsNCT03289962 2026-05-29
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genentech, Inc.
Phase 1 Completed
NCT03483012 2026-04-21
Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis
Dana-Farber Cancer Institute
Phase 2 Completed
NCT04732598 2026-04-21
AMBITION
Japanese Foundation for Cancer Research
Phase 3 Completed
NCT02530489 2026-02-17
Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04148911 2025-12-26
EL1SSAR
Hoffmann-La Roche
Phase 3 Completed
NCT03371017 2025-11-12
IMpassion132
Hoffmann-La Roche
Phase 3 Completed
NCT03280563 2025-11-10
MORPHEUS HR+BC
Hoffmann-La Roche
Phase 1/2 Completed
NCT03802604 2025-09-09
PROMETEO
SOLTI Breast Cancer Research Group
Phase EARLY_PHASE1 Completed
NCT03568656 2025-08-08
Study to Evaluate CCS1477 in Advanced Tumours
CellCentric Ltd.
Phase 1/2 Completed
NCT03206203 2024-12-12
Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT02708680 2024-12-04
Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
Syndax Pharmaceuticals
Phase 1/2 Completed
NCT03726879 2024-11-05
IMpassion050
Hoffmann-La Roche
Phase 3 Completed
NCT03800836 2024-10-30
A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Hoffmann-La Roche
Phase 1 Completed
NCT03164993 2024-10-15
ALICE
Oslo University Hospital
Phase 2 Completed
NCT03395899 2024-06-18
ECLIPSE
Queen Mary University of London
Phase 2 Completed
NCT04408118 2024-06-04
ATRACTIB
MedSIR
Phase 2 Completed
NCT03256344 2024-05-14
Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
Amgen
Phase 1 Completed
NCT03650348 2024-04-22
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
Pieris Pharmaceuticals, Inc.
Phase 1 Completed
NCT04177108 2024-03-27
A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT03125902 2024-03-26
IMpassion131
Hoffmann-La Roche
Phase 3 Completed
NCT02620280 2024-03-06
NeoTRIPaPDL1
Fondazione Michelangelo
Phase 3 Completed
NCT03853707 2024-02-20
Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer
City of Hope Medical Center
Phase 1/2 Completed
NCT03197935 2023-10-26
IMpassion031
Hoffmann-La Roche
Phase 3 Completed
NCT03464942 2023-07-19
AZTEC
Peter MacCallum Cancer Centre, Australia
Phase 2 Completed
NCT03841110 2023-05-01
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Completed
NCT04584112 2023-03-15
A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
Hoffmann-La Roche
Phase 1 Completed
NCT05609903 2022-11-08
Anastase
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Completed
NCT03232593 2022-08-24
A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
Hoffmann-La Roche
Completed
NCT02425891 2022-07-19
A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)
Hoffmann-La Roche
Phase 3 Completed
NCT02914470 2021-10-19
PROLOG
The Netherlands Cancer Institute
Phase 1 Completed
NCT02924883 2021-02-17
KATE2
Hoffmann-La Roche
Phase 2 Completed
NCT02605915 2020-02-05
Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Hoffmann-La Roche
Phase 1 Completed